Bedrijfsoverzicht
Phaos Technology Holdings (Cayman) Limited, operating through its Singapore-based subsidiary Phaos Technology Pte. Ltd., specializes in the manufacturing and commercialization of advanced microscopy-related solutions, technologies, and products designed for the medical device sector. The company functions within the Healthcare sector, specifically targeting the Medical Devices industry, which implies a focus on equipment and instrumentation used for clinical diagnostics and research applications. The organization maintains a compact operational scale with a market capitalization of $26.04M, trailing twelve-month revenue of $167,707, and an employee base of 25 individuals. These valuation and revenue figures indicate that the company operates as a small-cap entity with limited revenue generation relative to its market capitalization, suggesting a structure typical of early-stage biotechnology or specialized equipment firms that may prioritize product development over immediate profit scaling. The disparity between the $26.04M market cap and the $167,707 annual revenue highlights a significant premium attached to future growth expectations rather than current operational earnings, a common characteristic in capital-intensive medical technology sectors where assets and intellectual property are valued ahead of cash flow realization.
Financiële gezondheid
The company reported revenue of $167,707 and a net income of $-5,137,064 for the trailing twelve months, while EBITDA stood at $-3,869,313, revealing a substantial gap where non-operating expenses or significant amortization of intangible assets are likely driving the net loss far beyond operating losses. The free cash flow is reported at $-1,657,362, indicating that the company is currently burning cash, which severely limits its financial flexibility and ability to fund operations without external capital injections. Margin analysis shows a gross margin of 22.1%, suggesting that production costs consume a significant portion of revenue, while the operating margin of -1897.8% and profit margin of 0.0% reflect extreme operational inefficiencies or heavy one-time charges that have decoupled operating expenses from revenue generation. The balance sheet presents a complex picture with cash holdings of $177,660 against total debt of $3.26M, and a debt-to-equity ratio listed as N/A, which suggests the company is highly leveraged relative to its equity base given the negative equity implied by the negative price-to-book ratio. Liquidity is constrained further by a current ratio of 0.40, indicating that current assets are insufficient to cover current liabilities without relying on asset sales or new financing. Return metrics demonstrate severe capital inefficiency with a return on equity of -1073.1% and a return on assets of -71.2%, revealing that management has not yet generated positive returns on either shareholder equity or the asset base, a common but risky situation for private or early-stage medical device companies.
Waarderingsbeoordeling
Trailing P/E and forward P/E ratios are both listed as N/A due to the absence of positive earnings, meaning traditional earnings-based valuation multiples cannot be applied to assess the current earnings trajectory or expected earnings improvement. The price-to-book ratio is -31.87, a negative figure that indicates the market values the company at a significant premium over its book value, or conversely, that the book value is negative due to accumulated losses and intangible asset impairments, rendering the multiple mathematically anomalous for a standard valuation model. Alternative valuation metrics such as the price-to-sales ratio of 155.29 and an EV/EBITDA of -13.43 suggest that the market is pricing the stock entirely on speculative future potential rather than current sales or cash flow performance. The stock has traded within a 52-week range between a high of $7.39 and a low of $0.53, and without a specific current price provided in the facts, the position relative to this range cannot be precisely calculated, though the wide spread suggests high volatility typical of small-cap medical stocks. Beta is listed as N/A, meaning there is no available data to quantify the stock's price volatility relative to the broader market, making it impossible to assess systematic risk based on historical correlation with the market index.
Growth & Income
Revenue growth year-over-year is -93.1%, while earnings growth is N/A, indicating that the company is experiencing a drastic contraction in sales and lacks the historical earnings data to calculate a meaningful earnings growth rate. The negative revenue growth implies that the company is struggling to maintain its market position or is facing significant headwinds in the microscopy solutions market, while the inability to calculate earnings growth due to N/A data suggests earnings are either zero or negative, preventing any assessment of whether earnings are growing faster or slower than revenue. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company does not distribute income to shareholders, implying that all available cash, including the existing cash balance, is retained for reinvestment into research and development or to service its debt obligations. The overall growth and income profile is characterized by significant negative revenue momentum and a complete absence of dividend income, presenting a high-risk scenario where shareholder value is expected to be derived solely from potential future operational turnaround rather than current income generation or capital appreciation.